Biodesix (BDSX) Competitors

Biodesix logo
$8.88 -0.12 (-1.33%)
Closing price 04:00 PM Eastern
Extended Trading
$8.95 +0.07 (+0.79%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BDSX vs. TACO, VMD, INFU, XGN, and PARK

Should you buy Biodesix stock or one of its competitors? Biodesix's main competitors and comparable companies include Berto Acquisition (TACO), Viemed Healthcare (VMD), InfuSystem (INFU), Exagen (XGN), and Park Dental Partners (PARK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Biodesix compare to Berto Acquisition?

Biodesix (NASDAQ:BDSX) and Berto Acquisition (NASDAQ:TACO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

21.0% of Biodesix shares are owned by institutional investors. 23.2% of Biodesix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Biodesix has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market. Comparatively, Berto Acquisition has a beta of 0.07, suggesting that its share price is 93% less volatile than the broader market.

Berto Acquisition has a net margin of 0.00% compared to Biodesix's net margin of -25.74%. Berto Acquisition's return on equity of 0.00% beat Biodesix's return on equity.

Company Net Margins Return on Equity Return on Assets
Biodesix-25.74% -442.34% -29.16%
Berto Acquisition N/A N/A N/A

Berto Acquisition has lower revenue, but higher earnings than Biodesix.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biodesix$88.50M1.11-$35.26M-$2.76N/A
Berto AcquisitionN/AN/AN/AN/AN/A

Biodesix presently has a consensus price target of $34.20, indicating a potential upside of 285.14%. Given Biodesix's stronger consensus rating and higher possible upside, equities research analysts clearly believe Biodesix is more favorable than Berto Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biodesix
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86
Berto Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Biodesix had 15 more articles in the media than Berto Acquisition. MarketBeat recorded 20 mentions for Biodesix and 5 mentions for Berto Acquisition. Berto Acquisition's average media sentiment score of 0.97 beat Biodesix's score of 0.14 indicating that Berto Acquisition is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biodesix
2 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Berto Acquisition
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Biodesix beats Berto Acquisition on 9 of the 13 factors compared between the two stocks.

How does Biodesix compare to Viemed Healthcare?

Viemed Healthcare (NASDAQ:VMD) and Biodesix (NASDAQ:BDSX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, valuation and profitability.

Viemed Healthcare has a net margin of 5.03% compared to Biodesix's net margin of -25.74%. Viemed Healthcare's return on equity of 10.64% beat Biodesix's return on equity.

Company Net Margins Return on Equity Return on Assets
Viemed Healthcare5.03% 10.64% 7.73%
Biodesix -25.74%-442.34%-29.16%

Viemed Healthcare currently has a consensus target price of $12.00, suggesting a potential upside of 32.30%. Biodesix has a consensus target price of $34.20, suggesting a potential upside of 285.14%. Given Biodesix's stronger consensus rating and higher probable upside, analysts plainly believe Biodesix is more favorable than Viemed Healthcare.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viemed Healthcare
0 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.20
Biodesix
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86

74.2% of Viemed Healthcare shares are held by institutional investors. Comparatively, 21.0% of Biodesix shares are held by institutional investors. 20.6% of Viemed Healthcare shares are held by company insiders. Comparatively, 23.2% of Biodesix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Biodesix had 17 more articles in the media than Viemed Healthcare. MarketBeat recorded 20 mentions for Biodesix and 3 mentions for Viemed Healthcare. Viemed Healthcare's average media sentiment score of 0.33 beat Biodesix's score of 0.14 indicating that Viemed Healthcare is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Viemed Healthcare
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Biodesix
2 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Viemed Healthcare has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market. Comparatively, Biodesix has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market.

Viemed Healthcare has higher revenue and earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viemed Healthcare$270.28M1.27$14.93M$0.3823.87
Biodesix$88.50M1.11-$35.26M-$2.76N/A

Summary

Viemed Healthcare beats Biodesix on 11 of the 17 factors compared between the two stocks.

How does Biodesix compare to InfuSystem?

InfuSystem (NYSE:INFU) and Biodesix (NASDAQ:BDSX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, profitability and media sentiment.

71.1% of InfuSystem shares are held by institutional investors. Comparatively, 21.0% of Biodesix shares are held by institutional investors. 10.8% of InfuSystem shares are held by insiders. Comparatively, 23.2% of Biodesix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Biodesix had 18 more articles in the media than InfuSystem. MarketBeat recorded 20 mentions for Biodesix and 2 mentions for InfuSystem. InfuSystem's average media sentiment score of 0.24 beat Biodesix's score of 0.14 indicating that InfuSystem is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
InfuSystem
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Biodesix
2 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

InfuSystem currently has a consensus price target of $17.50, suggesting a potential upside of 18.32%. Biodesix has a consensus price target of $34.20, suggesting a potential upside of 285.14%. Given Biodesix's higher possible upside, analysts clearly believe Biodesix is more favorable than InfuSystem.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InfuSystem
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Biodesix
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86

InfuSystem has higher revenue and earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InfuSystem$144.44M2.05$870K$0.4532.87
Biodesix$88.50M1.11-$35.26M-$2.76N/A

InfuSystem has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market. Comparatively, Biodesix has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market.

InfuSystem has a net margin of 1.12% compared to Biodesix's net margin of -25.74%. InfuSystem's return on equity of 2.78% beat Biodesix's return on equity.

Company Net Margins Return on Equity Return on Assets
InfuSystem1.12% 2.78% 1.41%
Biodesix -25.74%-442.34%-29.16%

Summary

InfuSystem beats Biodesix on 12 of the 17 factors compared between the two stocks.

How does Biodesix compare to Exagen?

Exagen (NASDAQ:XGN) and Biodesix (NASDAQ:BDSX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability and risk.

Exagen has higher earnings, but lower revenue than Biodesix. Exagen is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Exagen$66.57M1.44-$19.95M-$0.75N/A
Biodesix$88.50M1.11-$35.26M-$2.76N/A

Exagen has a net margin of -25.14% compared to Biodesix's net margin of -25.74%. Exagen's return on equity of -125.60% beat Biodesix's return on equity.

Company Net Margins Return on Equity Return on Assets
Exagen-25.14% -125.60% -33.46%
Biodesix -25.74%-442.34%-29.16%

Exagen presently has a consensus target price of $9.88, indicating a potential upside of 162.63%. Biodesix has a consensus target price of $34.20, indicating a potential upside of 285.14%. Given Biodesix's higher probable upside, analysts clearly believe Biodesix is more favorable than Exagen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Exagen
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.89
Biodesix
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86

Exagen has a beta of 2.25, indicating that its stock price is 125% more volatile than the broader market. Comparatively, Biodesix has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market.

In the previous week, Exagen had 15 more articles in the media than Biodesix. MarketBeat recorded 35 mentions for Exagen and 20 mentions for Biodesix. Exagen's average media sentiment score of 0.41 beat Biodesix's score of 0.14 indicating that Exagen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Exagen
10 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Neutral
Biodesix
2 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

75.3% of Exagen shares are held by institutional investors. Comparatively, 21.0% of Biodesix shares are held by institutional investors. 10.4% of Exagen shares are held by company insiders. Comparatively, 23.2% of Biodesix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Exagen beats Biodesix on 11 of the 16 factors compared between the two stocks.

How does Biodesix compare to Park Dental Partners?

Park Dental Partners (NASDAQ:PARK) and Biodesix (NASDAQ:BDSX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

In the previous week, Biodesix had 11 more articles in the media than Park Dental Partners. MarketBeat recorded 20 mentions for Biodesix and 9 mentions for Park Dental Partners. Park Dental Partners' average media sentiment score of 0.43 beat Biodesix's score of 0.14 indicating that Park Dental Partners is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Park Dental Partners
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Biodesix
2 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

21.0% of Biodesix shares are owned by institutional investors. 10.6% of Park Dental Partners shares are owned by insiders. Comparatively, 23.2% of Biodesix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Park Dental Partners has higher revenue and earnings than Biodesix. Park Dental Partners is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Park Dental Partners$255.04M0.36-$360K-$1.91N/A
Biodesix$88.50M1.11-$35.26M-$2.76N/A

Park Dental Partners currently has a consensus price target of $28.50, suggesting a potential upside of 47.21%. Biodesix has a consensus price target of $34.20, suggesting a potential upside of 285.14%. Given Biodesix's stronger consensus rating and higher probable upside, analysts clearly believe Biodesix is more favorable than Park Dental Partners.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Park Dental Partners
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50
Biodesix
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86

Park Dental Partners has a net margin of -1.21% compared to Biodesix's net margin of -25.74%. Park Dental Partners' return on equity of 30.03% beat Biodesix's return on equity.

Company Net Margins Return on Equity Return on Assets
Park Dental Partners-1.21% 30.03% 4.25%
Biodesix -25.74%-442.34%-29.16%

Summary

Biodesix beats Park Dental Partners on 8 of the 15 factors compared between the two stocks.

Get Biodesix News Delivered to You Automatically

Sign up to receive the latest news and ratings for BDSX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BDSX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BDSX vs. The Competition

MetricBiodesixHealthcare Providers & Services IndustryHealthcare SectorNASDAQ Exchange
Market Cap$98.48M$10.57B$7.74B$11.62B
Dividend YieldN/A2.54%2.46%4.43%
P/E Ratio-3.2235.7734.1629.83
Price / Sales1.112.088.485.62
Price / CashN/A23.3421.9322.50
Price / Book11.383.594.373.66
Net Income-$35.26M$332.46M$3.52B$392.18M
7 Day Performance-11.38%-4.03%-5.43%-4.26%
1 Month Performance-62.47%-1.76%-4.54%-6.73%
1 Year Performance12.12%18.97%-1.42%-7.08%

Biodesix Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BDSX
Biodesix
3.8567 of 5 stars
$8.88
-1.3%
$34.20
+285.1%
+12.5%$98.48M$88.50MN/A334
TACO
Berto Acquisition
N/A$10.52
0.0%
N/A+3.3%$343.00MN/AN/A7,892
VMD
Viemed Healthcare
4.044 of 5 stars
$8.99
+0.4%
$12.00
+33.5%
+43.2%$341.52M$270.28M23.601,382
INFU
InfuSystem
2.7335 of 5 stars
$14.63
-0.4%
$17.50
+19.7%
+55.5%$295.16M$144.44M243.79473
XGN
Exagen
4.0601 of 5 stars
$5.12
-27.8%
$10.13
+97.6%
-58.2%$124.03M$66.57MN/A220

Related Companies and Tools


This page (NASDAQ:BDSX) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners